It has been reported to simultaneously inhibit the mTOR and vascular endothelial growth factor (VEGF) pathways in lymphatic malformations, demonstrating efficacy in many cases even those without mTOR activation [1,19]. This evidence concerns the gene MTOR and lymphatic malformation.